Pappas Capital Announces the Passing of…

 
Anthera Pharmaceuticals Licenses Japan Rights for Blisibimod to Zenyaku Kogyo Co., Ltd.

- Anthera to receive up to $48,000,000 plus future product margin on commercial supply
- Zenyaku to reimburse Anthera for a portion of future blisibimod worldwide development costs
- Zenyaku to assume full responsibility for development and associated costs in Japan and potentially other Asian territories in the future
- Companies will collaborate on blisibimod development for both IgA Nephropathy ("IgAN") and Systemic Lupus Erythematosus ("Lupus")

HAYWARD, Calif., Dec. 15, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) announced today that Anthera and Zenyaku Kogyo Co., Ltd. of Tokyo, Japan executed an exclusive license agreement for the development and commercialization of subcutaneous blisibimod in Japan and potentially other countries throughout Asia. Anthera retains full development and commercialization rights for all other global territories including North America and the European Union. Zenyaku currently markets Rituxan™, an anti-CD20 antibody, in Japan where it is approved for CD20 Positive B-Cell Lymphoma, B-cell Lymphoproliferative disorder, ANCA associated vasculitis (GPA, MPA), and Pediatric Nephrotic Syndrome.